Based on our previous findings in which we uncovered IL-6 and type 2 macrophages as the regulators of post-burn browning, we envisioned that blocking IL-6 signaling via the use of an IL-6 receptor-neutralizing (IL-6R) antibody might be therapeutically beneficial in alleviating both WAT browning and hepatic steatosis. Here, IL6R is linked to fatty liver disease.